Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical ...

The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11 in the US market following approval.

This research article is published in the Case Reports in Clinical Radiology, published by Scientific Scholar.Neuroendocrine tumours (NETs) affecting the extrahepatic bile ducts are ...

A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance ...

1 Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China 2 Zhejiang Cancer Hospital ... or late-stage, low-grade (G1 and G2), well-differentiated pNETs and extrapancreatic ...

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are uncommon and heterogeneous ... However, there was no significant difference in tumor grade between insulinomas and OF-PNETs (Table 2). The ...

Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand Center of Excellence for Innovation in Chemistry, Chiang Mai University, Chiang Mai 50200, Thailand ...

Cabozantinib is newly approved for neuroendocrine tumors, particularly beneficial for pancreatic, lung, and small bowel NETs Notable Insights: Dr Halfdanarson highlighted that small, ...

current semi-supervised methods often produce highly uncertain and erroneous predictions in the boundary regions of brain tumors due to their variable shapes, uneven distribution, and complex ...

These guidelines are for the management of grade 1 to grade 3 metastatic gastroenteropancreatic neuroendocrine tumors. These guidelines include the management of the different aspects and the symptoms ...

Most patients died before 2 years of follow-up. Patient with longer survival died at 35 months after diagnosis. CONCLUSION Neuroendocrine esophageal tumors are rare; affect mainly men in their sixties ...